R R

What Is Rydapt?

Rydapt is a prescription targeted medication containing midostaurin, a multikinase inhibitor used to treat selected blood cancers and mast cell disorders. It is approved for adults with newly diagnosed acute myeloid leukemia carrying an FLT3 mutation when used with specified chemotherapy. Rydapt is also approved for aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. It is supplied as 25 mg oral capsules taken with food. Midostaurin affects several kinase pathways involved in abnormal cell growth and survival. Treatment requires monitoring for blood count abnormalities, gastrointestinal effects, and potentially serious lung complications.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rydapt?

Rydapt is a prescription targeted medication containing midostaurin, a multikinase inhibitor used to treat selected blood cancers and mast cell disorders. It is approved for adults with newly diagnosed acute myeloid leukemia carrying an FLT3 mutation when used with specified chemotherapy. Rydapt is also approved for aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. It is supplied as 25 mg oral capsules taken with food. Midostaurin affects several kinase pathways involved in abnormal cell growth and survival. Treatment requires monitoring for blood count abnormalities, gastrointestinal effects, and potentially serious lung complications.

read more about rydapt ...

Copy this HTML:

Copy HTML Copied!

How Does Rydapt Work?

Rydapt inhibits several protein kinases involved in cellular growth and signaling. These include FLT3, KIT, and certain other kinases that may contribute to abnormal cell proliferation. In FLT3-mutated acute myeloid leukemia, midostaurin interferes with signals that support leukemia cell survival and growth. In advanced systemic mastocytosis, its activity against abnormal KIT-related signaling can reduce the proliferation and activity of mast cells. The medication's effects depend on the underlying disease and genetic characteristics. Rydapt does not cure every form of leukemia or mastocytosis. Its action on multiple kinase pathways may also contribute to treatment-related adverse effects.

What Conditions Does Rydapt Treat?

Rydapt is approved for adults with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive, as confirmed by an FDA-approved test. For this indication, it is used with standard cytarabine and daunorubicin induction chemotherapy and cytarabine consolidation chemotherapy. Rydapt is not indicated as a single-agent induction treatment for AML. It is also approved for adults with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast cell leukemia. These disorders involve abnormal accumulation or activity of mast cells and may affect multiple organs. A hematologist or oncologist confirms the diagnosis and evaluates treatment eligibility.

How Should Rydapt Be Taken?

Rydapt is taken orally twice daily with food. For newly diagnosed FLT3 mutation-positive acute myeloid leukemia, the recommended dose is 50 mg twice daily on days eight through 21 of each induction and consolidation chemotherapy cycle. For aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast cell leukemia, the recommended dose is 100 mg twice daily until disease progression or unacceptable toxicity. Capsules must be swallowed whole and should not be opened or crushed. Anti-nausea medication may be prescribed before treatment. Strong CYP3A inhibitors can increase midostaurin exposure, while strong enzyme inducers should be avoided. Treatment schedules and blood tests are managed by the oncology team.

What Are the Side Effects and Warnings of Rydapt?

Common adverse effects include nausea, vomiting, diarrhea, fatigue, headache, and swelling. Patients receiving Rydapt with chemotherapy may also experience low blood cell counts, fever, infections, and mucosal inflammation. Serious pulmonary toxicity, including interstitial lung disease and pneumonitis, has been reported and can be fatal. Rydapt can also cause embryo-fetal harm, requiring pregnancy precautions and effective contraception. Clinicians monitor blood counts, liver function, symptoms of infection, and breathing difficulties during treatment. New or worsening cough, unexplained shortness of breath, persistent fever, or severe gastrointestinal symptoms requires prompt medical evaluation.

Common Questions About Rydapt

Is Rydapt the same as midostaurin?

Yes. Rydapt is the brand name for midostaurin, a multikinase inhibitor used for selected blood cancers and advanced mast cell disorders.

Can Rydapt treat acute myeloid leukemia?

Yes. Rydapt is approved for adults with newly diagnosed FLT3 mutation-positive AML when used with specified induction and consolidation chemotherapy.

Can Rydapt treat systemic mastocytosis?

Yes. Rydapt is approved for aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia in adults.

Can Rydapt be taken without food?

Rydapt should be taken with food. Capsules must be swallowed whole without opening or crushing them.

References

DailyMed - RYDAPT (midostaurin) capsule, liquid filled. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11fa3fc9-6776-49a6-b1c1-653f627c3e58. Date Accessed November 4, 2026.

Midostaurin. MedlinePlus. https://medlineplus.gov/druginfo/meds/a617033.html. Date Accessed November 4, 2026.

Midostaurin. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/midostaurin. Date Accessed November 4, 2026.

Midostaurin. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/9829523. Date Accessed November 4, 2026.

Rydapt. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt. Date Accessed November 4, 2026.